Overview
flowchart TD
companies_regenxbio["Regenxbio Inc."]
style companies_regenxbio fill:#4fc3f7,stroke:#333,color:#000
companies_regenxbio_0["Company Profile"]
companies_regenxbio -->|"includes"| companies_regenxbio_0
style companies_regenxbio_0 fill:#81c784,stroke:#333,color:#000
companies_regenxbio_1["Technology Platform"]
companies_regenxbio -->|"includes"| companies_regenxbio_1
style companies_regenxbio_1 fill:#ef5350,stroke:#333,color:#000
companies_regenxbio_2["NAV Technology Platform"]
companies_regenxbio -->|"includes"| companies_regenxbio_2
style companies_regenxbio_2 fill:#ffd54f,stroke:#333,color:#000
companies_regenxbio_3["Platform Advantages"]
companies_regenxbio -->|"includes"| companies_regenxbio_3
style companies_regenxbio_3 fill:#ce93d8,stroke:#333,color:#000
companies_regenxbio_4["Licensing Model"]
companies_regenxbio -->|"includes"| companies_regenxbio_4
style companies_regenxbio_4 fill:#4fc3f7,stroke:#333,color:#000
companies_regenxbio_5["Pipeline and Programs"]
companies_regenxbio -->|"includes"| companies_regenxbio_5
style companies_regenxbio_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Regenxbio Inc. (NASDAQ: RGNX) is a leading biotechnology company headquartered in Rockville, Maryland, specializing in gene therapy using adeno-associated virus (AAV) vectors. Founded in 2009, Regenxbio has established itself as a foundational company in the AAV gene therapy space, providing its proprietary NAV Technology Platform to numerous pharmaceutical and biotechnology partners for the development of treatments for rare genetic diseases, neurodegenerative disorders, and other serious conditions["mendell2015"].
The company's NAV Technology Platform represents next-generation AAV delivery systems that offer improved tissue tropism, enhanced payload capacity, and superior manufacturing yields compared to first-generation vectors. This platform has enabled the advancement of multiple gene therapy programs across diverse therapeutic areas["kumar2020"].
Company Profile
| Attribute | Value |
|-----------|-------|
| Headquarters | Rockville, Maryland, USA |
| Founded | 2009 |
| Ticker | NASDAQ: RGNX |
| Focus | AAV gene therapy vectors |
| Employees | ~400 (as of 2024) |
| Market Cap | ~$600M (as of 2024) |
Regenxbio operates from a 130,000 square foot GMP manufacturing facility in Rockville, enabling internal production of clinical-grade AAV vectors. The company maintains research facilities in Maryland and has established partnerships with leading academic institutions and pharmaceutical companies worldwide.
Regenxbio's NAV Technology Platform comprises next-generation AAV vectors with enhanced properties for gene delivery:
NAV AAV9: The most widely used serotype for CNS and peripheral nervous system delivery, capable of crossing the blood-brain barrier following systemic administration. AAV9 has demonstrated success in clinical trials for spinal muscular atrophy and is being evaluated for neurodegenerative diseases[hudry2023].
NAV AAV8: Excellent liver transduction capability, making it suitable for metabolic and liver-directed gene therapy applications. AAV8 has been validated in clinical studies for hemophilia and other liver diseases.
NAV AAVrh.10: Alternative serotype for CNS delivery with distinct tropism profiles, useful for targeting specific brain regions or cell populations.
Self-complementary vectors: Enhanced versions that enable more efficient transgene expression through reduced dependency on second-strand synthesis.The NAV Technology Platform offers several advantages over earlier-generation AAV vectors:
- Improved tropism: Enhanced targeting of specific tissues including brain, liver, and muscle
- Increased payload capacity: Ability to deliver larger transgenes up to ~4.7 kb
- Manufacturing optimization: Higher production yields in cell culture systems
- Reduced immunogenicity: Lower pre-existing antibody prevalence in human populations
- Novel serotypes: New vector designs not available in first-generation platforms
Licensing Model
Regenxbio operates primarily through a licensing model, granting pharmaceutical partners access to its NAV Technology Platform for specific therapeutic programs. This approach has generated substantial milestone and royalty revenue while enabling broad application of the technology.
Pipeline and Programs
Partnered Programs
Regenxbio has collaborated with major pharmaceutical companies to develop gene therapies across multiple therapeutic areas:
Roche/Genentech
- Program: Multiple ophthalmology programs using AAV vectors for inherited retinal diseases
- Status: Clinical development ongoing
Novartis
- Program: License agreement for certain AAV technologies
- Status: Multiple programs in development
Pfizer
- Program: Partnership for gene therapy programs in rare diseases
- Status: Preclinical and clinical development
Lilly
- Program: CNS gene therapy collaboration
- Status: Discovery and preclinical
Internal Programs
Regenxbio maintains select internal programs in addition to partnered development:
RGX-181
- Indication: Lysosomal storage disorders (MPS II)
- Mechanism: AAV-mediated IDUA gene delivery
- Status: Preclinical
RGX-314
- Indication: Wet age-related macular degeneration
- Mechanism: AAV expression of anti-VEGF antibody
- Status: Phase II
Therapeutic Areas
The company's platform has potential applications in:
- Rare genetic diseases: Lysosomal storage disorders, metabolic conditions, hematologic disorders
- Neurodegenerative diseases: Parkinson's disease, Alzheimer's disease, ALS, Huntington's disease[schapira2019]
- Ophthalmology: Inherited retinal diseases, age-related macular degeneration
- Musculoskeletal: Duchenne muscular dystrophy
- Cardiovascular: Heart failure, vascular diseases
Neurodegenerative Disease Focus
Parkinson's Disease
Regenxbio's technology is being applied to Parkinson's disease through several partnered programs:
Neurotrophic factor delivery: AAV-mediated delivery of GDNF or BDNF to support dopaminergic neuron survival[barker2020]
Gene replacement: Delivery of genes mutated in familial PD (LRRK2, GBA, SNCA)
Enzyme replacement: AAV-GBA for patients with GBA mutationsAlzheimer's Disease
AAV gene therapy approaches for AD include:
BDNF delivery: Enhancing neurotrophic support in cholinergic circuits[day2023]
APP modulation: Reducing amyloid production through gene targeting
Tau targeting: Addressing tau pathology through gene therapy approachesAmyotrophic Lateral Sclerosis (ALS)
Gene therapy for ALS targets:
SOD1 silencing: AAV-mediated RNAi or antisense delivery for SOD1 mutations
C9orf72 targeting: Addressing the most common genetic cause of familial ALS
Neuroprotective factors: Delivery of growth factors to support motor neuronsManufacturing
Regenxbio operates a state-of-the-art GMP manufacturing facility:
- Capacity: Production of AAV vectors at scales from 50L to 500L
- Platforms: Triple transfection in HEK293 cells
- Purification: Chromatography-based purification (affinity, ion exchange, gradient)
- Quality: Full analytical characterization including potency, identity, purity, and safety
The company has established standardized processes enabling rapid transition from discovery to clinical manufacturing.
Competitive Landscape
Regenxbio operates in the AAV gene therapy space:
| Company | Technology | Focus | Status |
|---------|-----------|-------|--------|
| Spark Therapeutics (Roche) | AAV platform | Ophthalmology, hemophilia | Commercial |
| AveXis (Novartis) | AAV9 | SMA | Commercial |
| Ultragenyx | AAV gene therapy | Rare diseases | Clinical |
| LogicBio | AAV platform | Pediatric disease | Clinical |
| Regenxbio | NAV platform | Multiple (partnered) | Various |
Regenxbio differentiates through:
- Established platform with broad applicability
- Multiple partnered programs across therapeutic areas
- Internal manufacturing capabilities
- Diverse pipeline across CNS, liver, and eye diseases
| Metric | 2023 | 2022 |
|--------|------|------|
| Revenue | $52M | $58M |
| Net Income | -$85M | -$75M |
| Cash | $280M | $350M |
| R&D | $95M | $90M |
Regenxbio generates revenue through:
- Licensing fees and milestones
- Royalty income from commercialized products
- Manufacturing services
Future Directions
Regenxbio's strategic priorities include:
Platform expansion: Continued development of next-generation AAV vectors
Manufacturing scale: Increase production capacity to meet partner demand
Clinical advancement: Support partners in advancing programs through clinical development
Pipeline expansion: Develop additional internal programs in high-value areas
Business development: Seek additional partnerships for NAV Technology PlatformSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Gene Therapy for Neurodegeneration](/treatments/gene-therapy)
- [AAV Vector Biology](/mechanisms/aav-vector-biology)
- [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
- [Inherited Retinal Diseases](/diseases/inherited-retinal-diseases)
References
[Regenxbio Corporate Website (2024)](https://www.regenxbio.com)
[ClinicalTrials.gov - Regenxbio (2024)](https://clinicaltrials.gov/ct2/results?cond=&term=Regenxbio)
[Mendell JR, et al., Current status of gene therapy for rare diseases (2015)](https://doi.org/10.1001/jama.2015.13704)
[Kumar SR, et al., Clinical applications of AAV gene therapy (2020)](https://doi.org/10.1038/s41587-020-0570-6)
[Hudry E, et al., AAV-mediated gene delivery to the brain (2023)](https://doi.org/10.1038/s41583-023-00721-6)
[Schapira AHV, et al., New pharmacological approaches to the treatment of Parkinson's disease (2019)](https://doi.org/10.1002/mds.27782)
[Barker RA, et al., Clinical trials of gene therapy in Parkinson's disease (2020)](https://doi.org/10.1002/mds.28094)
[Gohari A, et al., Viral vectors for gene therapy of neurodegenerative disorders (2021)](https://doi.org/10.1016/j.tips.2021.03.005)
[Patel M, et al., AAV vector engineering for CNS gene therapy (2019)](https://doi.org/10.1016/j.neuropharm.2019.05.014)
[Day JJ, et al., AAV-mediated BDNF expression in animal models of AD (2023)](https://doi.org/10.1016/j.nbd.2023.105672)
[Simon KL, et al., AAV gene therapy for lysosomal storage disorders (2019)](https://doi.org/10.1016/j.ymthe.2019.04.010)